Mammary Cell News Volume 4.29 | Jul 26 2012

LABORATORY RESEARCH

Activation of an IL6 Inflammatory Loop Mediates Trastuzumab Resistance in HER2+ Breast Cancer by Expanding the Cancer Stem Cell Population
Researchers generated trastuzumab resistant cells by knocking down PTEN expression in HER2 overexpressing breast cancer cell lines and demonstrated that development of trastuzumab resistance in these cells is mediated by activation of an IL6 inflammatory feedback loop leading to expansion of the cancer stem cell population. [Mol Cell] Abstract | Press Release

Activation of Robo1 Signaling of Breast Cancer Cells by Slit2 from Stromal Fibroblast Restrains Tumorigenesis via Blocking PI3K/Akt/β-Catenin Pathway
Investigators report that the tumorigenic potential of breast cancer cells is determined by an interaction between the Robo1 receptor and its ligand Slit2, which is secreted by stromal fibroblasts. [Cancer Res] Abstract

Transducer of Cdc42-Dependent Actin Assembly Promotes Breast Cancer Invasion and Metastasis
Scientists report that the adaptor protein transducer of Cdc42-dependent actin assembly-1 is expressed in highly invasive breast cancers and regulates their metastatic phenotypes. [Oncogene] Abstract

Integrin β5 Contributes to the Tumorigenic Potential of Breast Cancer Cells through the Src-Focal Adhesion Kinase and MEK-Extracellular Signal-Regulated Kinase Signaling Pathways
Scientists investigated the role of integrin β5 in breast carcinomas by depleting integrin β5 using RNA interference and reexpression of integrin β5. [Oncogene] Abstract

Anti-Tumor Activity of Phenethyl Isothiocyanate in HER2 Positive Breast Cancer Models
Researchers evaluated the effects of phenethyl isothiocyanate in HER2-positive breast cancer cells. [BMC Med] Abstract | Full Article

The Resveratrol Analogue 4,4′-Dihydroxy-Trans-Stilbene Suppresses Transformation in Normal Mouse Fibroblasts and Inhibits Proliferation and Invasion of Human Breast Cancer Cells
Researchers investigated the effects of 4,4’-dihydroxy-trans-stilbene both on chemical-induced transformation of BALB/c 3T3 mouse fibroblasts and on the proliferation and invasion of human breast cancer MCF-7 cells. [Carcinogenesis] Abstract

Targeted Polymersome Delivery of siRNA Induces Cell Death of Breast Cancer Cells Dependent upon Orai3 Protein Expression
Researchers report on the encapsulation and delivery of siRNA inside of peptide functionalized polymersomes composed of poly(1,2-butadiene)-b-poly(ethylene oxide). [Langmuir] Abstract

RhoC Impacts the Metastatic Potential and Abundance of Breast Cancer Stem Cells
Scientists identified RhoC GTPase as an important regulator of breast cancer stem cell (BCSC) metastasis, and present evidence suggesting that RhoC also modulates the frequency of BCSCs within a population. [PLoS One] Full Article | Press Release

Modulation of MicroRNA-194 and Cell Migration by HER2-Targeting Trastuzumab in Breast Cancer
Researchers suggest that trastuzumab treatment upregulates microRNA-194 (miR-194) expression and may exert its cell migration-inhibitory effect through miR-194-mediated downregulation of cytoskeleton protein talin2 in HER2-overexpressing human breast cancer cells. [PLoS One] Full Article

CLINICAL RESEARCH

Six Cycles of Doxorubicin and Cyclophosphamide or Paclitaxel Are Not Superior to Four Cycles as Adjuvant Chemotherapy for Breast Cancer in Women with Zero to Three Positive Axillary Nodes: Cancer and Leukemia Group B 40101
A Cancer and Leukemia Group B trial 40101 was conducted using a phase III factorial design to define whether six cycles of a chemotherapy regimen are superior to four cycles. Researchers also aimed to determine whether paclitaxel is as efficacious as doxorubicin/cyclophosphamide, but with reduced toxicity. [J Clin Oncol] Abstract

Phase IB Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Women with Hormone Receptor-Negative Breast Cancer
Scientists conducted a phase IB dose escalation trial in women with a history of stage I-III hormone receptor-negative breast cancer of an oral green tea extract, Polyphenon E 400 mg, 600 mg, 800 mg bid or matching placebo for six months. [Cancer Prev Res] Abstract

Distinguished Researcher Receives More than $5.6 Million from National Institutes of Health
The National Institutes of Health has awarded Florida Agricultural and Mechanical University College of Pharmacy and Pharmaceutical Sciences an important and major grant from the National Institute on Minority Health and Health Disparities. The research funded by this grant will address novel approaches for treating and preventing breast and lung cancer and promote minority health. [Florida Agricultural And Mechanical University] Press Release

EntreMed Announces Initiation of Phase II Trial in Triple-Negative Breast Cancer
EntreMed, Inc. announced the initiation of a dual-institutional Phase II study of ENMD-2076 in triple-negative breast cancer. The study is sponsored by EntreMed and is supported by a grant from the National Cancer Institute. [EntreMed, Inc.] Press Release

HALO Healthcare Finalizes License Agreement with University of North Dakota for Cancer Detection Biomarkers
HALO Healthcare, Inc. announced that it has signed a definitive license agreement with the University of North Dakota to develop biomarkers for the early detection of breast cancer. [Business Wire] Press Release

Aurora Imaging Technology Announces Exclusive China Distributor Agreement with Sumec Group Corporation
Aurora Imaging Technology, Inc. announced an exclusive China distribution agreement with the Sumec Group Corporation. This agreement gives both companies a platform to expand China’s rapidly rising diagnostic and screening markets for breast MRI. [Aurora Imaging Technology, Inc.] Press Release

BioFocus Expands Its Drug Discovery Offering with Proteomics Technology from Activiomics
BioFocus and Activiomics announced a strategic alliance which will allow BioFocus to offer its customers Activiomics’ proteomics services to improve identification of novel targets for drug discovery and biomarkers for diagnostics. [Activiomics Ltd] Press Release

bioTheranostics Adds Chief Commercial Officer & VP of Corporate Development
bioTheranostics, Inc. announced that Mary Jo Mullen, chief commercial officer, and Isaac J. Bright, M.D., vice president (VP), corporate development, have joined the company’s senior management team. [bioTheranostics, Inc.] Press Release

Advisory Panel Upholds Recommendation to Withdraw Bevacizumab Approval for Breast Cancer
A panel of experts advising the Food and Drug Administration (FDA) recommended unanimously that the agency withdraw its accelerated approval of bevacizumab for treating metastatic breast cancer. [National Cancer Institute, United States] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW Women’s Health 2013: The 21^st Annual Congress
March 22-24, 2013
Washington, United States

Visit our events page to see a complete list of events in the mammary cell community.

Quality Control Operations Coordinator (STEMCELL Technologies, Inc.)

Research Associate – Chemistry (STEMCELL Technologies, Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies, Inc.)

Research Technologist – Contract Assay Services (STEMCELL Technologies, Inc.)

Research Technologist – Media Development (STEMCELL Technologies, Inc.)

Research Technologist – Research and Development (STEMCELL Technologies, Inc.)

Scientific Communications & Publishing Coordinator (STEMCELL Technologies, Inc.)

Scientist – Epithelial Cell Research (STEMCELL Technologies, Inc.)

Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies, Inc.)

Scientist – hPSC Bioengineering (STEMCELL Technologies Inc.)

Scientist – Mesenchymal Cell Research (STEMCELL Technologies, Inc.)

Postdoctoral Position – Gene Regulation in Breast Cancer/Stem Cell Biology (University of Cincinnati)

Assistant Professor – Oncology/Breast Cancer (University of Chicago)

Associate Professor – Metastatic Breast Cancer (University of Colorado Comprehensive Cancer Center)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.